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Letter to the Editor 
Diagnostic Hematology
Clinical Utility of Bone Marrow Study in Gaucher 
Disease: A Case Report of Gaucher Disease Type 3 With 
Intractable Myoclonic Seizures
John Hoon Rim, M.D.1, Minyoul Baik, M.D.2, Sun Och Yoon, M.D.3, Kyoung Heo, M.D.2, and Jaewoo Song, M.D.1
Departments of Laboratory Medicine1, Neurology2, and Pathology3, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Dear Editor,
Gaucher disease (GD) is the most common lysosomal storage 
disease, characterized by glucosylceramide accumulation in 
macrophages owing to inherited glucocerebrosidase deficiency 
caused by GBA1 mutation [1]. Clinical manifestations include 
thrombocytopenia, hepatosplenomegaly, bone pain, osteopenia, 
dyspnea, and seizure, depending on the organ involved [2]. 
Among these, neurologic involvement plays a crucial role in the 
classification of the following three subtypes: GD types 1, 2, and 
3, called non-neuronopathic, acute neuronopathic, and chronic 
neuronopathic types, respectively [1, 2]. β-glucocerebrosidase 
activity in peripheral leukocyte is considered the confirmatory 
diagnostic indicator of GD [2]. Bone marrow (BM) study to de-
tect Gaucher cells (GCs) with the classical “wrinkled tissue pa-
per” appearance has not been routinely recommended because 
of procedural risks and false-positive results [3]. We present a 
patient with recurrent seizures as a sole symptom who was cor-
rectly diagnosed as having GD type 3 through a BM study.
A 31-yr-old woman with recurrent seizures was referred to our 
hospital. She experienced the first seizure attack at the age of 
23 yr. Despite constant antiepileptic medications at the outpa-
tient clinic, she had drug-resistant myoclonic seizures, intermit-
tently evolving to generalized tonic-clonic seizures, which re-
quired 11 hospital admissions during the last three years. The 
initial complete blood count showed no specific findings other 
than mild leukopenia, with the following values: hemoglobin, 
11.9 g/dL; platelets, 162×109/L; and leukocytes, 3.32×109/L, 
with normal differential counts (Fig. 1A). Physical examination 
and abdominal ultrasonography revealed no evidence of sple-
nomegaly or hepatomegaly. Drug-induced leukopenia related 
with long-term use of antiepileptic medications was initially sus-
pected, but the patient showed mild leukopenia during the re-
cent eight weeks, with leukocyte levels ranging from 3.00×109/
L to 3.59 ×109/L. Accordingly, the attending physician per-
formed a BM study.
In hypocellular marrow with normal distribution, GCs ac-
counted for 17.5% of all nucleated cells on the aspiration smear 
(Fig. 1B). Of the GCs, 10.5% showed atypical vacuolations, 
while the others showed typical fibrillary cytoplasm with an ec-
centrically placed nucleus (Fig. 1C). Despite the consistent BM 
biopsy findings of GCs (Fig. 1D), reticulin staining showed no 
evidence of abnormal reticulin fibrosis (i.e., grade 0). In addi-
tion, β-glucocerebrosidase activity test revealed 0.6 nmol/hr/mg 
protein, which is much lower than the reference limit of 6.0 
nmol/hr/mg protein. GBA1 sequencing to confirm the diagnosis 
revealed two point mutations (i.e., N188S and R257Q), both 
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previously reported as the cause of GD. Under the diagnosis of 
GD type 3, the patient was given enzyme replacement therapy 
with imiglucerase (Cerezyme, Genzyme Corporation, Cam-
bridge, MA, USA), and her leukocyte count returned to normal. 
However, the neurological symptoms did not alleviate, coincid-
ing with the fact that imiglucerase is well known to be unable to 
penetrate the blood-brain barrier.
Owing to the phenotypic variability of GD, which might hinder 
prompt diagnosis or timely clinical impression, several guide-
lines for optimal diagnostic algorithm and evaluation steps have 
been suggested [4, 5]. Regardless of GD subtypes, hepato-
splenomegaly and thrombocytopenia were considered as the 
most common clinical features. Therefore, hematologic aspects 
of GD have been emphasized for the early diagnosis of prevent-
able complications [2, 6]. Even though the clinical utility of BM 
study in GD is controversial, GCs detected in BM have been the 
most important diagnostic indicator in our patient. The long sei-
zure history was explained on the basis of the BM finding, which 
suggests the reappraisal of the clinical utility of BM study in GD 
despite professionally appropriate evaluation.
Atypical GCs in BM of type 1 GD were evaluated by using the 
cytomorphological approach in a recent study, in which seven 
types, including foamy cytoplasm, multinuclearity, erythropha-
gocytosis, and cytoplasmic projections, were described [7]. The 
authors suggested that foamy transformation of GCs might be 
associated with an abnormal storage pattern triggered by an ex-
Fig. 1. Microscopic examination of the patient’s (A) peripheral blood (×400, Wright-Giemsa stain) and (B) bone marrow aspiration (×400, 
Wright-Giemsa stain). (C) Atypical Gaucher cell with vacuolations and typical Gaucher cell with a “wrinkled tissue pattern” on bone marrow 
aspirate smear (×1,000, Wright-Giemsa stain). (D) Bone marrow biopsy specimen presenting with several Gaucher cells (×400, Hematoxy-
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ternal factor, possibly seizure attacks in this case. Another re-
cent study focused on the differential clinical utilities of BM bi-
opsy and aspiration to detect the presence of GCs [8]. Although 
biopsy seemed more sensitive to GCs, our patient showed a 
comparable percentage of GCs in aspiration and biopsy, which 
might be related to the absence of abnormal reticulin fibrosis in 
this case.
In conclusion, we report a GD patient with recurrent seizures 
as the single classical symptom, in whom GC detected in BM in-
dicated the correct diagnosis of GD. Our case might emphasize 
the clinical utility of BM study for GD, especially in cases of un-
explained seizures without prominent hematologic abnormalities. 
Further studies to investigate the roles of BM study for GD for 
monitoring enzyme replacement therapy response are expected.
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